{
  "docId": "019de072-c7f4-719d-b60b-87ffd56a191c",
  "docSlug": "e58df8a62ccd3bd6cd3ca8f1cf8222ea",
  "documentTitle": "MindMed | Results Presentation Deck | 40 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 40,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-c7f4-719d-b60b-87ffd56a191c/33",
  "deckHref": "/decks/019de072-c7f4-719d-b60b-87ffd56a191c",
  "deckJsonHref": "/decks/019de072-c7f4-719d-b60b-87ffd56a191c.json",
  "deckAnchorHref": "/decks/019de072-c7f4-719d-b60b-87ffd56a191c#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.13,
        "w": 0.68,
        "x": 0.16,
        "y": 0.204
      },
      "kind": "callout",
      "text": "Phase 1 study results support progression of MM-110 (zolunicant) into planned upcoming Phase 2 clinical program",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db541be8-d93c-4594-bc54-cf33c4a2c01e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.662,
        "x": 0.169,
        "y": 0.436
      },
      "kind": "list",
      "text": "Well-tolerated up to 500 mg per day in Single Ascending Dose (SAD) and 60 mg per day in the Multiple Ascending Dose (MAD)\nLinear PK maintained across the tested doses and frequencies\nClinical effects align with potent CNS engagement\nQOD regimen aligns with preclinical evidence & offers potential to be a more effective regimen in opioid withdrawal",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee228673-95d3-4dbb-a1c1-53270b402596",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.435,
        "x": 0.058,
        "y": 0.048
      },
      "kind": "title",
      "text": "MM-110 | Phase 1 Study Results - Key Takeaways",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f110f48-0686-414c-81d3-906f14e4f1d8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 33,
      "from": 17,
      "beatId": "8b3edd16-18bb-4450-a68c-0765c795a4f7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 17-33 present Zolunicant as a potential solution.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}